Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study

J Am Acad Dermatol. 2022 Oct;87(4):920-922. doi: 10.1016/j.jaad.2021.12.039. Epub 2021 Dec 30.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Antirheumatic Agents* / adverse effects
  • Cohort Studies
  • Humans
  • Injections, Subcutaneous
  • Methotrexate* / adverse effects
  • Patient Reported Outcome Measures
  • Prospective Studies
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Methotrexate